VANGUARD GROUP INC - GENMARK DIAGNOSTICS INC ownership

GENMARK DIAGNOSTICS INC's ticker is GNMK and the CUSIP is 372309104. A total of 87 filers reported holding GENMARK DIAGNOSTICS INC in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
VANGUARD GROUP INC ownership history of GENMARK DIAGNOSTICS INC
ValueSharesWeighting
Q1 2021$87,734,000
+33.6%
3,670,817
-18.4%
0.00%0.0%
Q4 2020$65,670,000
+5.9%
4,497,904
+3.0%
0.00%0.0%
Q3 2020$62,027,000
+13.3%
4,368,133
+17.3%
0.00%0.0%
Q2 2020$54,759,000
+361.8%
3,722,544
+29.3%
0.00%
+100.0%
Q1 2020$11,859,000
-22.1%
2,878,551
-9.0%
0.00%0.0%
Q4 2019$15,218,000
-10.1%
3,163,795
+13.2%
0.00%0.0%
Q3 2019$16,935,000
-3.6%
2,794,472
+3.3%
0.00%0.0%
Q2 2019$17,564,000
-9.1%
2,706,362
-0.7%
0.00%0.0%
Q1 2019$19,321,000
+44.6%
2,725,055
-0.9%
0.00%0.0%
Q4 2018$13,366,000
-30.4%
2,750,164
+5.2%
0.00%0.0%
Q3 2018$19,207,000
+16.8%
2,613,213
+1.4%
0.00%0.0%
Q2 2018$16,451,000
+19.5%
2,578,273
+1.9%
0.00%0.0%
Q1 2018$13,762,000
+35.3%
2,529,816
+3.7%
0.00%
Q4 2017$10,174,000
-55.3%
2,439,663
+3.3%
0.00%
-100.0%
Q3 2017$22,747,000
-11.4%
2,362,101
+8.9%
0.00%0.0%
Q2 2017$25,664,000
+2.3%
2,169,476
+10.9%
0.00%0.0%
Q1 2017$25,084,000
+8.0%
1,956,681
+3.1%
0.00%0.0%
Q4 2016$23,231,000
+18.8%
1,897,990
+14.5%
0.00%0.0%
Q3 2016$19,562,000
+37.0%
1,657,870
+1.0%
0.00%0.0%
Q2 2016$14,279,000
+76.3%
1,641,312
+6.8%
0.00%0.0%
Q1 2016$8,097,000
-29.8%
1,536,448
+3.4%
0.00%0.0%
Q4 2015$11,535,000
-95.0%
1,486,437
-83.9%
0.00%
-88.9%
Q3 2015$229,981,000
+1849.2%
9,258,055
+610.9%
0.01%
+800.0%
Q2 2015$11,799,000
-28.4%
1,302,316
+2.6%
0.00%0.0%
Q1 2015$16,476,000
+1.9%
1,269,398
+6.8%
0.00%0.0%
Q4 2014$16,169,000
+58.1%
1,188,058
+4.2%
0.00%0.0%
Q3 2014$10,228,000
-30.9%
1,140,207
+4.3%
0.00%0.0%
Q2 2014$14,797,000
+42.0%
1,093,631
+4.3%
0.00%0.0%
Q1 2014$10,422,000
-13.3%
1,048,468
+16.1%
0.00%0.0%
Q4 2013$12,017,000
+12.4%
902,858
+2.6%
0.00%0.0%
Q3 2013$10,696,000
+43.0%
880,348
+21.7%
0.00%0.0%
Q2 2013$7,478,000723,1560.00%
Other shareholders
GENMARK DIAGNOSTICS INC shareholders Q1 2017
NameSharesValueWeighting ↓
Casdin Capital, LLC 3,500,000$25,725,0003.13%
CADIAN CAPITAL MANAGEMENT, LP 3,830,399$28,153,0001.28%
Mesirow Financial Investment Management, Inc. 33,001$243,0001.25%
Bellevue Group AG 1,339,502$9,845,0000.62%
NEEDHAM INVESTMENT MANAGEMENT LLC 260,000$1,912,0000.58%
Lyon Street Capital, LLC 109,850$807,0000.50%
Private Wealth Partners, LLC 300,000$2,205,0000.34%
Penn Capital Management Company, LLC 455,064$3,345,0000.25%
HighTower Advisors, LLC 2,337,132$17,179,0000.12%
Schonfeld Strategic Advisors LLC 376,000$2,763,0000.12%
View complete list of GENMARK DIAGNOSTICS INC shareholders